• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Verastem Inc.

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    SC 13G 1 alyeska-vstm093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Verastem, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    92337C203

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Investment Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,859,954
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,859,954
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,859,954
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.11%*
    12
    TYPE OF REPORTING PERSON
     
    IA

     The reporting persons are the beneficial owners of 2,859,954 shares of Common Stock of the Issuer, which constitute approximately 7.11% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

     


     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Fund GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,859,954
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,859,954
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,859,954
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.11%*
    12
    TYPE OF REPORTING PERSON
     
    OO

     The reporting persons are the beneficial owners of 2,859,954 shares of Common Stock of the Issuer, which constitute approximately 7.11% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

     


     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Anand Parekh
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,859,954
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,859,954
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,859,954
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.11%*
    12
    TYPE OF REPORTING PERSON
     
    IN
    The reporting persons are the beneficial owners of 2,859,954 shares of Common Stock of the Issuer, which constitute approximately 7.11% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.
     


     

     

    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Verastem, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    4720 East Cotton Gin Loop, Suite 220

    Phoenix, Arizona 85040

    Item 2.(a) Names of Person Filing:

    (i) Alyeska Investment Group, L.P.

     

    (ii) Alyeska Fund GP, LLC

     

    (iii) Anand Parekh

      

    Item 2.(b) Address of Principal Business Office:

    (i) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (ii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (iii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

      

    Item 2.(c) Citizenship:

    (i) Alyeska Investment Group, L.P. - Delaware

     

    (ii) Alyeska Fund GP, LLC - Delaware

     

    (iii) Anand Parekh - United States of America

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.0001 par value per share

     

    Item 2.(e) CUSIP No.:

    92337C203

     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached hereto

    (c) Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto

     The reporting persons are the beneficial owners of 1,859,954 shares of Common Stock of the Issuer and hold warrants to purchase 1,000,000 shares of the Issuer’s Common Stock (the “Warrants”) as of September 30, 2024. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

    By:  Entity and Description

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           

     

     
    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           
    Get the next $VSTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    3/12/2026$19.00Buy
    BTIG Research
    2/4/2026$18.00Buy
    H.C. Wainwright
    10/16/2025Overweight
    Cantor Fitzgerald
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    More analyst ratings

    $VSTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on July 1, 2026. A t

    7/2/26 4:30:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

    Broad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or standard-of-care chemotherapy supports broad development strategy including combinations Favorable safety and tolerability profile characterized by predominately low-grade gastrointestinal adverse events that attenuate after cycle 1; favorable tolerability in combination regimens Verastem and Erasca announce their intent to evaluate VS-7375 in combination with ERAS-0015, Erasca’s investigational pan-RAS molecular glue, in advanced KRAS G12D-mutant solid tumors Company to

    6/23/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

    90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). KRAS is mutated in more than 90% of pancreatic cancers, mak

    6/17/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    SEC Filings

    View All

    SEC Form 144 filed by Verastem Inc.

    144 - Verastem, Inc. (0001526119) (Subject)

    6/25/26 4:01:36 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    6/23/26 4:02:33 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    6/17/26 8:52:16 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $VSTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BTIG Research resumed coverage on Verastem with a new price target

    BTIG Research resumed coverage of Verastem with a rating of Buy and set a new price target of $19.00

    3/12/26 8:55:19 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/24/24 4:00:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Paterson Dan sold $87,241 worth of shares (20,871 units at $4.18), decreasing direct ownership by 3% to 591,242 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    6/24/26 4:45:21 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Calkins Daniel sold $17,089 worth of shares (4,089 units at $4.18), decreasing direct ownership by 3% to 117,238 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    6/24/26 4:44:42 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Michael P was granted 108,000 shares (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    5/27/26 5:45:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verastem Inc.

    SC 13G - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Leadership Updates

    Live Leadership Updates

    View All

    Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026. "We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceutical and biotechnology companies, with a proven track record of taking oncology medicines from clinical development through successful commercialization, including landmark therapies like ERBITUX®," said Daniel Paterson, pre

    5/26/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    3/20/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Financials

    Live finance-specific insights

    View All

    VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

    Broad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or standard-of-care chemotherapy supports broad development strategy including combinations Favorable safety and tolerability profile characterized by predominately low-grade gastrointestinal adverse events that attenuate after cycle 1; favorable tolerability in combination regimens Verastem and Erasca announce their intent to evaluate VS-7375 in combination with ERAS-0015, Erasca’s investigational pan-RAS molecular glue, in advanced KRAS G12D-mutant solid tumors Company to

    6/23/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

    Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor conference call and webcast on Tuesday, June 23 at 4:30 pm ET to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D clinical program and updated preliminary data from the Phase 1/2 TARGET-D 101 dose escalation and dose expansion trial evaluating VS-7375 alone and in combination in patients wi

    6/15/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

    AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth Initiated Phase 2 registration-directed trials "VS-7375 TARGET-D Clinical Program" in 2L PDAC, 2L/3L NSCLC and 2L+ CRC VS-7375 TARGET-D 101 early data update expected in the first half of 2026; mature data update expected in the second half of 2026 Ended Q1 2026 with $181.7 million in cash, cash equivalents and investments; expected cash runway into first half of 2027 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medic

    5/7/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care